Elutia Inc (ELUT) Key Statistics & Financial Ratios

Elutia Inc (ELUT) — Price $0.81 HealthcareBiotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Elutia Inc (ELUT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.

Stock Data

Price$0.81
Market Cap$36M
Enterprise Value$26.7M
Beta0.71
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio0.61
Price / Book2.22
P/S2.91
EV/EBITDA-1.11
EV/Sales2.20
EV/FCF-0.59
P/FCF-0.78
Earnings Yield146.62%
FCF Yield-127.00%
Dividend Yield0.00%

Profitability

Gross Margin57.82%
EBIT Margin-212.90%
EBITDA Margin-198.86%
Operating Margin-194.03%
Net Margin426.93%
Return on Equity940.81%
Return on Assets118.69%
Return on Invested Capital-79.27%
Return on Capital Employed-104.16%

Financial Health

Current Ratio1.77
Quick Ratio1.64
Cash Ratio0.95
Debt / Equity0.69
Debt / Assets24.72%
Net Debt / EBITDA0.38
Interest Coverage6.77
Piotroski F-Score5
Altman Z-Score-3.65

Per-Share Data

Revenue per share0.28
Book Value per share0.36
Cash per share0.46
FCF per share-1.04
Tangible Book Value per share0.34
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy5
Hold0
Sell0
Strong Sell0
Total analysts5
Avg rating (1-5)1.00

Related companies: ANVS · BCAB · CALC · CELU · LTRN · MAIA · PYPD

Explore sector: Healthcare · Biotechnology

More sections of ELUT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks